Abstract
The purpose of this review is to outline recent developments in contrast agents for magnetic resonance angiography (MRA) and to give some idea of what the future might hold. Up to now, non-binding gadolinium (Gd) chelates have been the agents used for MRA. Modified paramagnetic Gd-based agents with varying degrees of protein interaction have been developed, and these, together with new superparamagnetic compounds, are currently under clinical evaluation. It is likely that two different types of contrast agent will soon be available: extracellular agents for first-pass MRA and intravascular agents mainly for steady-state MRA. Several agents also exhibit certain tissue specific properties in addition to conventional extracellular properties. This will lead to more comprehensive imaging approaches.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
